Study details
Enrolling now
Imaging Immune Activation in COVID-19
CellSight Technologies, Inc.
NCT IDNCT04815096ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
80
Study length
about 4.5 years
Ages
18+
Locations
1 site in CA
About this study
This trial is testing a treatment called [18F]F-AraG to see if it can show immune activation in people who have recovered from COVID-19. The treatment will be given as two intravenous doses, followed by imaging scans of the whole body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Infectious